

FRED UPTON, MICHIGAN
CHAIRMAN

HENRY A. WAXMAN, CALIFORNIA
RANKING MEMBER

ONE HUNDRED THIRTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-2927
Minority (202) 225-3641

June 5, 2013

Ms. Christine M. Simmon
Senior Vice President
Policy and Strategic Alliances
Generic Pharmaceutical Association
777 Sixth Street, N.W., Suite 510
Washington, D.C. 20001

Dear Ms. Simmon:


Thank you for appearing before the Subcommittee on Health on Thursday, April 25, 2013, to testify at the hearing entitled "Securing Our Nation's Prescription Drug Supply Chain."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions by the close of business on Wednesday, June 19, 2013. Your responses should be e-mailed to the Legislative Clerk in Word format at Sydne.Harwick@mail.house.gov and mailed to Sydne Harwick, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Joseph R. Pitts
Chairman
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachment

Attachment 1—Additional Questions for the Record

The Honorable John D. Dingell

1. Do you agree that a traceability system would help to better secure our drug supply chain from counterfeits, theft, and intentional adulteration? If no, please explain why.
2. Do you agree that a traceability system would help to identify and detect illegitimate pharmaceuticals? If no, please explain why.
3. Do you agree that a traceability system would help to ensure the safety of pharmaceuticals for patients and consumers? If no, please explain why.
4. Do you agree that a traceability system would improve the efficiency and effectiveness of recalls or returns? If no, please explain why.
5. Do you agree that a federal traceability system should be based on uniform, national standards? If no, please explain why.
6. Do you agree that a federal traceability system should include participation from everyone in the supply chain? Please explain why.
7. Do you agree that a federal traceability system should take a phased-in approach? If no, please explain why.
8. Do you agree that a federal traceability system with a phased-in approach should include clear requirements and a clear timeframe for a second phase? If no, please explain why.
9. Do you believe that a unit level traceability system is feasible at this time for all members of your industry? Please explain why.
10. Do you believe that a lot level traceability system is feasible at this time for all members of your industry? Please explain why.
11. Do you agree that the goal of any federal traceability system should be unit level tracing? If no, please explain why.
12. Do you believe that it is imperative that traceability legislation be passed this year? If no, please explain why.